FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

As a result, the market is dumping Sarepta stock, which is down -42% in trading so far today. Sarepta's current market cap valuation has fallen <$6bn, when at the beginning of this week, it had ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating on December 29. Joseph Schwartz ...

Wolfe Research initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT), currently valued at $2.06 billion in market cap, with a peerperform rating on Tuesday, setting a fair value of $19 per ...

When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. It usually first shows up in boys aged two to five years. Genetic alterations ...

What: Shares of Sarepta Therapeutics, a clinical-stage biopharmaceutical company actively engaged in finding cures for Duchenne muscular dystrophy (DMD) and other infectious diseases utilizing RNA ...

What happened Shares of the rare-disease drugmaker Sarepta Therapeutics (NASDAQ: SRPT) crashed and burned in May seemingly due to nothing more than a.

Wolfe Research initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT), currently valued at $2.06 billion in market cap, with a peerperform rating on Tuesday, setting a fair value of $19 per share ...